NeuroPace to Present at the Leerink Global Healthcare Conference

NeuroPace, Inc. (Nasdaq: NPCE), a pioneering medical device company headquartered in Mountain View, California, is set to present at the Leerink 2026 Global Healthcare Conference on March 11, 2026. The presentation will take place at 8:40 AM PT in Miami, FL, and aims to showcase the company's innovative approach to treating epilepsy through its groundbreaking RNS System, a brain-responsive technology designed to reduce or eliminate seizures in patients with drug-resistant epilepsy.

The RNS System is notable for being the first commercially available platform that delivers personalized, real-time treatment directly at the seizure source. This technology represents a significant advancement in epilepsy care, offering a solution for patients who do not respond to conventional drug therapies. Additionally, NeuroPace's focus on personalized medicine has the potential to improve outcomes for a broader range of patients suffering from various brain disorders.

During the conference, NeuroPace's management team will also conduct investor meetings, providing a platform for potential investors to engage directly with the company's leadership. The presentation will be accessible via live webcast, ensuring a wider audience can benefit from the insights shared. A replay of the event will be available for thirty days afterward on NeuroPace's investor website, allowing stakeholders to revisit the key points discussed.

NeuroPace represents a transformative approach to a critical healthcare issue affecting millions globally. With its innovative technology and commitment to improving patient care, the company is positioned as a leader in the epilepsy treatment landscape. Investors and industry professionals alike are encouraged to tune in to gain deeper insights into the advancements and future potential of NeuroPace's offerings.

NeuroPace, Inc. (Nasdaq: NPCE), poised to present at the upcoming Leerink Global Healthcare Conference, represents a compelling opportunity for investors in the burgeoning medical device sector focused on neurological disorders. The company specializes in transformative solutions for epilepsy management, addressing a significant unmet need in the market—drug-resistant epilepsy.

NeuroPace's patented RNS System stands out as a groundbreaking, brain-responsive platform, uniquely designed to deliver real-time, tailored treatments directly at seizure sources. This innovative technology has the potential to redefine the standard of care for epilepsy patients, offering them alternatives where traditional pharmaceuticals have failed. Given that approximately one-third of epilepsy cases resist drug treatment, NeuroPace’s RNS System could capture a substantial share of this underserved demographic, translating to sizable revenue growth.

Investors should note the strategic timing of the presentation. The 2026 Leerink Global Healthcare Conference not only attracts key industry stakeholders but also garners attention from healthcare investors looking for innovative solutions in a sector ripe with potential for expansion. Management's investor meetings further open up opportunities for stakeholder engagement, making this event crucial for building awareness and investor confidence.

As the landscape for neuromodulation and advanced medical devices evolves, NeuroPace is well-positioned to leverage partnerships and collaborations to enhance its market presence. However, potential investors must remain vigilant about regulatory challenges, competition from alternative therapies, and the broader market environment impacting small-cap biotech firms.

In summary, NeuroPace stands as a promising candidate for investment consideration. Its innovative approach to treating epilepsy, impressive potential market growth, and proactive investor engagement at the upcoming conference make it an attractive option for investors looking to capitalize on advancements in healthcare technology. Careful evaluation of biotech trends and ongoing developments in regulatory landscapes will be essential for informed investment decisions.